We and others have described how UNG protein depletion, or inhibition of its catalytic activity using the small UNG inhibitor protein (UGI), can significantly increase the potency of FdU or pemetrexed in human cancer cell lines (3–6, 8, 9). The gene discussed is UNG; the disease is cancer.